We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Vertex Pharmaceuticals (VRTX - Free Report) ended the recent trading session at $407.90, demonstrating a -1.05% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.4%. Meanwhile, the Dow experienced a drop of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.66%.
The drugmaker's stock has climbed by 5.33% in the past month, exceeding the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on November 3, 2025. The company's earnings per share (EPS) are projected to be $4.53, reflecting a 3.42% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $3.04 billion, indicating a 9.73% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $17.95 per share and revenue of $11.98 billion, which would represent changes of +4173.81% and +8.76%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.3% lower within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Vertex Pharmaceuticals is currently exchanging hands at a Forward P/E ratio of 22.97. Its industry sports an average Forward P/E of 19.66, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 88, placing it within the top 36% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know
Vertex Pharmaceuticals (VRTX - Free Report) ended the recent trading session at $407.90, demonstrating a -1.05% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 0.4%. Meanwhile, the Dow experienced a drop of 0.04%, and the technology-dominated Nasdaq saw an increase of 0.66%.
The drugmaker's stock has climbed by 5.33% in the past month, exceeding the Medical sector's gain of 1.8% and the S&P 500's gain of 1.02%.
Market participants will be closely following the financial results of Vertex Pharmaceuticals in its upcoming release. The company plans to announce its earnings on November 3, 2025. The company's earnings per share (EPS) are projected to be $4.53, reflecting a 3.42% increase from the same quarter last year. Alongside, our most recent consensus estimate is anticipating revenue of $3.04 billion, indicating a 9.73% upward movement from the same quarter last year.
For the full year, the Zacks Consensus Estimates are projecting earnings of $17.95 per share and revenue of $11.98 billion, which would represent changes of +4173.81% and +8.76%, respectively, from the prior year.
Investors should also pay attention to any latest changes in analyst estimates for Vertex Pharmaceuticals. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.3% lower within the past month. Vertex Pharmaceuticals is holding a Zacks Rank of #3 (Hold) right now.
From a valuation perspective, Vertex Pharmaceuticals is currently exchanging hands at a Forward P/E ratio of 22.97. Its industry sports an average Forward P/E of 19.66, so one might conclude that Vertex Pharmaceuticals is trading at a premium comparatively.
The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 88, placing it within the top 36% of over 250 industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow VRTX in the coming trading sessions, be sure to utilize Zacks.com.